Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences (REVB)
NASDAQ:REVB
REVB Stock Chart & Stats
$0.90
-$0.04(-6.62%)
At close: 4:00 PM EST
$0.90
-$0.04(-6.62%)
Day’s Range― - ―
52-Week Range$1.14 - $44.77
Previous CloseN/A
Volume326.26K
Average Volume (3M)740.56K
Market Cap
$4.43M
Enterprise Value-$9.95B
Total Cash (Recent Filing)$10.70B
Total Debt (Recent Filing)$746.78M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
May 08, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding3,720,420
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-2.25K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.70M
Enterprise Value/Ebitda-550.31
Forecast
1Y Price Target
$16.00Price Target Upside1677.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-14.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Innate-immunity PipelineA focused clinical-stage platform targeting innate immunity creates a durable strategic niche across respiratory viral infections and related indications. This platform orientation supports repeatable R&D application, potential multi-indication value capture, and clearer prioritization of clinical resources over the next 2–6 months.
Modest LeverageLow reported debt relative to equity provides structural financial flexibility for a pre-revenue biotech. With modest leverage, the company faces lower fixed interest burdens, preserving its ability to prioritize R&D spend and access capital markets without immediate solvency pressure over the medium term.
Completed Warrant FinancingA recent warrant inducement that generated ~$7.3M materially extends near-term runway and demonstrates management's ability to secure non-dilutive-today cash via financings. This structural capital infusion increases probability of advancing clinical milestones before next major financing, improving program continuity.
Bears Say
Pre-revenue ProfileNo product revenue leaves the company fully dependent on external capital to fund operations and trials. This structural reliance increases dilution and execution risk over time, reducing visibility into sustainable cash generation and making long-term planning contingent on successful raises or partnerships.
Persistent Cash BurnSustained negative operating and free cash flow, with a marked deterioration in the latest year, signals ongoing heavy R&D and operating outflows. This durable cash burn pattern necessitates frequent financing, compresses optionality for program prioritization, and elevates execution risk absent new funding.
Financial Statement DiscontinuityA material YoY discontinuity in equity and assets increases uncertainty about comparability and underlying financial stability. Such structural reporting shifts complicate forecasting, hinder trend analysis for investors and partners, and raise governance or accounting risk that can affect capital access.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $1.14 and its highest was $44.77 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $4.43M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is May 08, 2026 which is in 46 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on Feb 26, 2026. The company reported -$1.65 earnings per share for the quarter, beating the consensus estimate of -$3.66 by $2.01.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Undervalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -1.15.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 3,720,420 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$1.65 in its last earnings report, beating expectations of -$3.66. Following the earnings report the stock price went down -0.752%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
REVB Stock 12 Month Forecast
Average Price Target
$16.00
▲(1677.78% Upside)
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
56.11% Insiders
0.17% Mutual Funds
― Other Institutional Investors
43.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---